CSF2 and rheumatoid arthritis: Importantly, GM-CSF levels are increased in synovial fluid of RA patients [81], and a phase IIb clinical trial using a recombinant human anti-GM-CSF antibody in patients with moderate-to-severe RA has shown decreased disease activity [70].